Videos

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, discussed the changes that would take place if pharmacists were granted provider status for Medicare Part B.

Because there are no other available treatment options, Pamela Spicer said the approval of aducanumab gives much-needed hope to patients with Alzheimer disease and their families.

A panel of experts discuss how pharmacists can play a role in the nonpharmacologic treatment of dry eye disease.

Lisa M. Nijm, MD, JD, explains dry eye disease and its effects on a suffering patient.

Although she said it is unlikely that the FDA will retract the approval, prescribers could be reluctant to administer aducanumab to patients.

Pharmacy Times interviewed Dennis O’Neill, president and board member of BIOMEDICAN, on the outlook around the future of biosynthesis therapeutics that use rare cannabinoids to treat a range of health issues, from mental health disorders to diabetes.

Advice to community pharmacists and patients who suffer from migraine on strategies that can improve quality of life and be used to navigate the care continuum.

Red flags that would prompt a pharmacist to refer a patient with migraine to be evaluated by a physician.

What community pharmacists need to know about migraine treatment and their role in educating and managing patients.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss the emerging data around BCMA-targeted CAR T-cell therapy in multiple myeloma.

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, outlined what has led to legislation granting pharmacists provider status gaining bipartisan support.

In addition to concerns about the data supporting the FDA approval of aducanumab for patients with Alzheimer disease, FDA advisory committee members raised some unique concerns when they rejected the application in November 2020.

Zydelig (idelalisib) is a kinase inhibitor approved in 2014 for 3 oncology indications.

Despite the FDA's approval of aducanumab for the treatment of Alzheimer disease with mild cognitive impairments, it has been surrounded by questions.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed what changes would be necessary to continue providing quality virtual health care to patients with diabetes.

Clive Ward Able, MD, BPharm, president of Clintell, consultant to NeonMind Inc, and a trained pharmacist and physician, discusses his research into the use of psychedelic compounds to treat obesity.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, a clinical pharmacy specialist at Penn Medicine in the University of Pennsylvania Health System, and Andrew Lin, PharmD, BCOP, an oncology pharmacy specialist at Memorial Sloan-Kettering Cancer Center, to provide an overview of current CAR T-cell therapies.

Taylor M. Weis, PharmD, BCOP, discusses the role of pharmacists in toxicity prevention and management with BTK inhibitor therapy in CLL.

A review of long-term efficacy and safety data on the use of BTK inhibitor monotherapy in the frontline setting, plus insights from clinical practice.

Findings from the 2 pivotal phase 3 trials had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains.

Pharmacists and pharmacy technicians are perfectly positioned to help manage patients' transitions of care, according to experts with University of Michigan Health.

Panelists consider the goals of guideline-directed medical therapy and reflect on how recent updates to clinical practice guidelines may impact therapeutic pathways.

A thought leader in the pharmacologic management of heart failure, Alexandra Goncharenko, PharmD, BCPS, BCCP, reviews the mechanism of action of vericiguat and considers its place in the treatment landscape.

Examples of patient populations with improved medication adherence and savings achieved because of Prescription Discount Programs are discussed.

Experts discuss examples of financial challenges patients experience that impact medication adherence, and potential solutions to address these challenges.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss their presentation at the recent ATOPP 2021 summit on re-examining the why, who, and where of CAR T therapy.

Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said there are no other currently available treatments for Alzheimer disease that get to the root of the condition.

Pamela Spicer, senior analyst with Datamonitor Healthcare, said aducanumab is a once-monthly infusion with a 6-month titration schedule.

Dennis O’Neill, president and board member of BIOMEDICAN, discusses the current field of research assessing biosynthesis therapeutics that use psychedelics and rare cannabinoids.

An overview of CGRP antagonists approved as preventive therapy for migraine and recommendations for appropriate dosing and administration to patients.